Sanritatug clinical trials
How each study uses sanritatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sanritatug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Hangzhou Sumgen Biotech Co., Ltd. (5) · Mao Jianhua (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test sanritatug, phase 3 first.
- Mar 2027A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsPhase 3 · Hangzhou Sumgen Biotech Co., Ltd.
- Mar 2027Study of SG301 for Renal AMR After TransplantationPhase 2 · Hangzhou Sumgen Biotech Co., Ltd.
- Sep 2027To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusPhase 2 · Hangzhou Sumgen Biotech Co., Ltd.
Studies
Open first, then newest update. How each study uses sanritatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusRecruitingPhase 2Hangzhou Sumgen Biotech Co., Ltd.NCT07447986Written as SG301 SC Injection
- Study of SG301 for Renal AMR After TransplantationNot yet recruitingPhase 2Hangzhou Sumgen Biotech Co., Ltd.NCT07764627Written as SG301 Injection
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingPhase 3Hangzhou Sumgen Biotech Co., Ltd.NCT06508983Written as SG301 Injection
- A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid DependenceRecruitingPhase 2Mao JianhuaNCT07087314Written as SG301 Subcutaneous injection
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingPhase 1Hangzhou Sumgen Biotech Co., Ltd.NCT04684108Written as SG301
- SG301-SC Injection Safety Study in Subjects With Systemic Lupus ErythematosusCompletedPhase 1Hangzhou Sumgen Biotech Co., Ltd.NCT06144710Written as SG301 SC Injection
Codes
What other systems call sanritatug · ClinicalTrials.gg INT017666
- UNII (FDA) Q9T9JY086WSANRITATUGOne source FDA
- NCI Thesaurus C179569SanritatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Q9T9JY086W | SANRITATUG | One source FDA |
| NCI Thesaurus | C179569 | Sanritatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.